药物相关性颌骨坏死治疗方法的研究进展

doi:10.19438/j.cjoms.2020.05.017

中国口腔颌面外科杂志 ›› 2020, Vol. 18 ›› Issue (5): 474-477.doi: 10.19438/j.cjoms.2020.05.017

药物相关性颌骨坏死治疗方法的研究进展

姜钧健, 何悦

上海交通大学医学院附属第九人民医院·口腔医学院口腔颌面-头颈肿瘤科, 国家口腔疾病临床医学研究中心, 上海市口腔医学重点实验室, 上海市口腔医学研究所,上海 200011

收稿日期:2019-03-29 修回日期:2019-12-20 出版日期:2020-09-20 发布日期:2020-10-28
通讯作者: 何悦,Tel:021-23271699,E-mail: william5218@126.com
作者简介:姜钧健（1993-）,男,硕士研究生,E-mail: jiangjj0104@126.com
基金资助:
国家自然科学基金（81570949）

Research progress on treatment of medication-related osteonecrosis of the jaw

JIANG Jun-jian, HE Yue

Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology& Shanghai Research Institute of Stomatology. Shanghai 200011, China;

Received:2019-03-29 Revised:2019-12-20 Online:2020-09-20 Published:2020-10-28

摘要/Abstract

摘要： 药物相关性颌骨坏死是患者使用抗骨吸收或抗血管生成药物导致的并发症,破坏了口腔卫生,影响患者饮食、语音功能,降低生活质量。对MRONJ患者最恰当的治疗策略还未达成共识。本文就近年来药物相关性颌骨坏死的分期及辅助治疗方法的研究进展作一综述。

关键词: 药物相关性颌骨坏死, 双膦酸盐, 分期, 治疗

Abstract: Medication-related osteonecrosis of the jaw is a complication in patients taking antiresorptive or antiangiogenic drugs. It destroys oral hygiene, affects patients' eating, speech and reduces their quality of life. There is no consensus on the most appropriate treatment strategy for medication-related osteonecrosis of the jaw till now. This article summarized the recent research on staging and adjuvant treatment of medication-related osteonecrosis of the jaw.

Key words: Medication-related osteonecrosis of the jaw, Bisphosphonate, Staging, Therapy

中图分类号:

R782.3

姜钧健, 何悦. 药物相关性颌骨坏死治疗方法的研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(5): 474-477.

JIANG Jun-jian, HE Yue. Research progress on treatment of medication-related osteonecrosis of the jaw[J]. China J Oral Maxillofac Surg, 2020, 18(5): 474-477.

参考文献

[1] Stevenson M, Jones ML, De Nigris E, et al.A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis[J]. Health Technol Assess, 2005, 9(22): 1-160.
[2] Marx RE.Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9): 1115-1157.
[3] Greuter S, Schmid F, Ruhstaller T, et al.Bevacizumab-associated osteonecrosis of the jaw[J]. Ann Oncol, 2008, 19(12): 2091-2092.
[4] Koch FP, Walter C, Hansen T, et al.Osteonecrosis of the jaw related to sunitinib[J]. Oral Maxillofac Surg, 2011, 15(1): 63-66.
[5] Owosho AA, Scordo M, Yom SHK, et al.Osteonecrosis of the jaw a new complication related to Ipilimumab[J]. Oral Oncol, 2015, 51(12): e100-101.
[6] Ruggiero SL, Dodson TB, Fantasia J, et al.American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update[J]. J Oral Maxillofac Surg, 2014, 72(10): 1938-1956.
[7] Allen BW, Demchenko IT, Piantadosi CA.Two faces of nitric oxide: implications for cellular mechanisms of oxygen toxicity[J]. J Appl Physiol(1985), 2009, 106(2): 662-667.
[8] Piantadosi CA, Tatro LG.Regional H₂O₂ concentration in rat brain after hyperoxic convulsions[J]. J Appl Physiol(1985), 1990, 69(5): 1761-1766.
[9] Demchenko IT, Boso AE, O'Neill TJ, et al. Nitric oxide and cerebral blood flow responses to hyperbaric oxygen[J]. J Appl Physiol(1985), 2000, 88(4): 1381-1389.
[10] Demchenko IT, Boso AE, Whorton AR, et al.Nitric oxide production is enhanced in rat brain before oxygen-induced convulsions[J]. Brain Res, 2001, 917(2): 253-261.
[11] Boykin Jr JV, Baylis C.Hyperbaric oxygen therapy mediates increased nitric oxide production associated with wound healing: a preliminary study[J]. Adv Skin Wound Care, 2007, 20(7): 382-388.
[12] Freiberger JJ.Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws[J]. J Oral Maxillofac Surg, 2009, 67(5 Suppl): 96-106.
[13] Freiberger JJ, Padilla-Burgos R, McGraw T, et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics[J]. J Oral Maxillofac Surg, 2012, 70(7): 1573-1583.
[14] Delanian S.Striking regression of radiation-induced fibrosis by a combination of pentoxifylline and tocopherol[J]. Br J Radiol, 1998, 71(848): 892-894.
[15] Delanian S, Depondt J, Lefaix JL.Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase Ⅱ trial[J]. Head Neck, 2005, 27(2): 114-123.
[16] Delanian S, Porcher R, Rudant J, et al.Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis[J]. J Clin Oncol, 2005, 23(34): 8570-8579.
[17] Epstein MS, Wicknick FW, Epstein JB, et al.Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2010, 110(5): 593-596.
[18] Magremanne M, Reychler H.Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis[J]. J Oral Maxillofac Surg, 2014, 72(2): 334-337.
[19] Owosho AA, Estilo CL, Huryn JM, et al.Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016, 122(4): 455-459.
[20] Ripamonti CI, Cislaghi E, Mariani L, et al.Efficacy and safety of medical ozone (O₃) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: preliminary results of a phase Ⅰ-Ⅱstudy[J]. Oral Oncol, 2011, 47(3): 185-190.
[21] Agrillo A, Filiaci F, Ramieri V, et al.Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy[J]. Eur Rev Med Pharmacol Sci, 2012, 16(12): 1741-1747.
[22] Cheung A, Seeman E.Teriparatide therapy for alendronate-associated osteonecrosis of the jaw[J]. N Engl J Med, 2010, 363(25): 2473-2474.
[23] Dayisoylu EH, Senel FÇ, Üngör C, et al.The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study[J]. Int J Oral Maxillofac Surg, 2013, 42(11): 1475-1480.
[24] Kim KM, Park W, Oh SY, et al.Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw[J]. Osteoporos Int, 2014, 25(5): 1625-1632.
[25] Kakehashi H, Ando T, Minamizato T, et al.Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings[J]. Int J Oral Maxillofac Surg, 2015, 44(12): 1558-1564.
[26] Badran Z, Abdallah MN, Torres J, et al.Platelet concentrates for bone regeneration: Current evidence and future challenges[J]. Platelets, 2018, 29(2): 105-112.
[27] Tsai LL, Huang YF, Chang YC.Treatment of bisphosphonate-related osteonecrosis of the jaw with platelet-rich fibrin[J]. J Formos Med Assoc, 2016, 115(7): 585-586.
[28] Adornato MC, Morcos I, Rozanski J.The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors[J]. J Am Dent Assoc, 2007, 138(7): 971-977.
[29] Curi MM, Cossolin GSI, Koga DH, et al.Bisphosphonate-related osteonecrosis of the jaws-an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma[J]. J Oral Maxillofac Surg, 2011, 69(9): 2465-2472.
[30] Fernando de Almeida Barros Mourão C, Calasans-Maia MD, Del Fabbro M, et al. The use of Platelet-rich fibrin in the management of medication-related osteonecrosis of the jaw: a case series[J]. J Stomatol Oral Maxillofac Surg, 2020, 121(1):84-89.
[31] Giudice A, Barone S, Giudice C, et al.Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2018, 126(5): 390-403.
[32] Nφrholt SE, Hartlev J.Surgical treatment of osteonecrosis of the jaw with the use of platelet-rich fibrin: a prospective study of 15 patients[J]. Int J Oral Maxillofac Surg, 2016, 45(10): 1256-1260.

药物相关性颌骨坏死治疗方法的研究进展

Research progress on treatment of medication-related osteonecrosis of the jaw

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	邱银秀, 代天国, 徐波, 程进强, 刘忠龙. 重症口腔颌面头颈部多间隙感染临床分类探讨[J]. 中国口腔颌面外科杂志, 2023, 21(2): 125-130.
[2]	金夏悦, 顾迎新. 骨质疏松对口腔种植修复影响的研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(1): 81-86.
[3]	周瑜, 翁海燕, 司呈云, 段贤捷, 安星妃, 章礼玉. 第8版TNM分期修订版对早期口腔黏膜鳞癌患者预后及危险分层作用的临床研究[J]. 中国口腔颌面外科杂志, 2022, 20(6): 571-576.
[4]	庞超远, 马东洋, 张文凯, 王兵武, 刘东. 54例学龄前儿童颌面部骨折临床分析[J]. 中国口腔颌面外科杂志, 2022, 20(6): 586-589.
[5]	吴亚平, 高嘉敏, 孙树洋. HPV相关口咽癌诊疗进展[J]. 中国口腔颌面外科杂志, 2022, 20(6): 599-606.
[6]	樊文慧, 劳峥, 石慧烽, 毕帆, 涂文勇, 胡海生. 3D打印可分离式口腔支架在口腔癌放疗中的摆位准确性研究[J]. 中国口腔颌面外科杂志, 2022, 20(5): 466-470.
[7]	马玉洁, 余敏杰, 宋赛文, 张馨月, 蔡宜倞, 陈洁, 袁勇翔, 蒋灿华. 外伤致下颌骨髁突颅内移位：病例报告及文献复习[J]. 中国口腔颌面外科杂志, 2022, 20(5): 513-516.
[8]	游元和, 田卓炜, 杜仲, 肖孟, 许贵松, 郑家伟, 王延安. 靶向YAP协同强化selumetinib抑制神经纤维瘤相关施万细胞生长的体外研究[J]. 中国口腔颌面外科杂志, 2022, 20(4): 347-353.
[9]	朱柏恺, 刘旌毅, 吕政展, 郑美里, 汪席均, 河奈玲, 江凌勇. 关节功能板联合正颌-正畸治疗对特发性髁突吸收患者上气道结构变化的影响[J]. 中国口腔颌面外科杂志, 2022, 20(4): 354-359.
[10]	李恒勇, 杨宋, 周凯, 孔钰, 李洁莹, 李贵忠, 葛胜优, 杨小琛, 冯元勇, 宋凯, 尚伟. 336例HPV相关性与非相关性口咽鳞癌患者生存分析[J]. 中国口腔颌面外科杂志, 2022, 20(4): 378-383.
[11]	张益益, 杨玥怡, 琚梧桐, 钟来平. 局部晚期口腔鳞癌新辅助免疫靶向治疗2例及文献复习[J]. 中国口腔颌面外科杂志, 2022, 20(4): 413-416.
[12]	刘冰, 何悦, 彭歆, 孙长伏, 韩正学, 吴煜农, 彭利伟, 赵熠, 陶谦, 韩新光, 李劲松, 苏彤, 李波, 张雷, 胡砚平, 陈传俊, 李一, 李铁军, 赵怡芳. 牙源性角化囊肿诊疗中国专家共识[J]. 中国口腔颌面外科杂志, 2022, 20(3): 209-218.
[13]	韩如雪, 马旭辉, 李智, 任国欣, 郭伟, 吴云腾, 梁翔. 2种活检方法对156例口腔黏膜恶性黑色素患者预后的影响[J]. 中国口腔颌面外科杂志, 2022, 20(3): 235-238.
[14]	褚珺, 胡明, 王国民, 吕挺正. 19例合并凝血功能异常的腭裂患儿围术期处理[J]. 中国口腔颌面外科杂志, 2022, 20(3): 282-286.
[15]	陈一铭, Ahmed, 季彤, 任振虎. 101例头颈部横纹肌肉瘤临床、病理及预后分析[J]. 中国口腔颌面外科杂志, 2022, 20(2): 146-150.